ClinicalTrials.gg
Status unknownNCT04027764Updated Jul 22, 2019

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

A Phase 2 interventional study of Toripalimab Combined With S1 and Albumin Paclitaxel in Advanced Biliary Tract Cancer, sponsored by Dai, Guanghai. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-22.

Sponsored by Dai, Guanghai · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Biliary Tract Neoplasms with a site in China — 94 open to participants now, 112 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Planned enrollment
128th of 158
30 · median 61
Started
2019
with 7 others
Phase 2
95 of 177
53 open now
Registered
31st of 177
by date

Among the 177 studies in Biliary Tract Neoplasms with a site in China, this one is the 128th largest by planned enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2019, is one of 95 in phase 2, and was the 31st registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

94 of the 177 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

The investigator's study is a single armed phrase II trial ,aiming to improve the effecacy of treatment for advanced billiary tract cancer by means of Toripalimab combining with S1 and Albumin Paclitaxel as first line in patients with advanced Biliary Tract Cancer. treatment continually until disease progression or intolerable toxicity or Patients withdrawal of consent.and target sample is 30+ patients.

Read the detailed description

Toripalimab: 240 mg , once every 2-3 weeks; S1: 80-120mg, bid; oral, day1-14; Albumin paclitaxel: 120mg/m2 , administered on the first day and the eighth day of each cycle; 21 days for a treatment cycle

03

Conditions studied

  • Advanced Biliary Tract Cancer

Keywords

  • advanced biliary tract cancer
  • Albumin Paclitaxel
  • s1
  • Toripalimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old
  2. Patients with gallbladder and cholangiocarcinoma diagnosed by histology or cytology
  3. Liver function grade A (5-6 points) or better grade B (≤ 7 points)
  4. score 0 or 1 point
  5. At least one
  6. no previous treatment

Exclusion criteria

Exclusion Criteria:

  1. organs failure ,including liver ,heart ,kidney
  2. Have received a liver transplant in the past
  3. Active or spinal cord compression
  4. score 3 or 4 point
  5. Symptomatic peripheral neuropathy ( ≥ 2)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Toripalimab Combined With S1 and Albumin Paclitaxel

    Drug: Toripalimab Combined With S1 and Albumin Paclitaxel

Interventions

  • DrugToripalimab Combined With S1 and Albumin Paclitaxel

    Toripalimab 240 mg ,every 2-3 weeks S1:80-120mg,bid;oral,d1-14; Albumin Paclitaxel:120mg/m2,D 1 \\8

    Also known as: TSA

06

What researchers measure

Primary outcomes

  1. objective response rate

    ORR

    Time frame: 1 year

Secondary outcomes

  1. progression free survival

    PFS

    Time frame: 1 year

  2. disease response rate

    DCR

    Time frame: 1 year

  3. overall survival

    OS

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for May 2020, 12 months after the start.

Of 101 non-industry phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 60. This study's planned 12 months is below that.

Counting every sponsor, half of 132 studies reached it within 39 months; a quarter within 29 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 22, 2019
StartActual
May 1, 2019
Primary completionEst.
May 1, 2020
CompletionEst.
May 1, 2021
Last update
Jul 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04027764
Lead sponsor
Dai, Guanghai
Responsible party
Dai, Guanghai (professor,deputy cheif of oncology department, Chinese PLA General Hospital) — Sponsor-investigator
First posted
Jul 22, 2019
Start date
May 1, 2019
Primary completion
May 1, 2020 (estimated)
Completion
May 1, 2021 (estimated)
Last update
Jul 22, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion